Trevi Therapeutics TRVI 深 沪
等待开盘 10-07 09:30:00 美东时间
13.20
-0.520
-3.79%
华盛通- 最 高13.83
- 今 开13.83
- 成交量 95.35万股
- 最 低 12.995
- 昨 收 13.72
- 总市值 18.81亿
- 52周最高 20.22
- 市盈率 静 --
- 换手率 0.67%
- 52周最低 9.82
- 委 比 42.53%
- 总股本 1.42亿
- 历史最高 20.22
- 量 比 0.64
- 振 幅 6.09%
- 历史最低 0.46
- 每 手 1
- 风险率 2.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Trevi Therapeutics announced the acceptance of two abstracts for presentation at the European Respiratory Society (ERS) Congress 2026. Professor Marlies Wijsenbeek will present oral findings from the Phase 2b CORAL trial, assessing quality of life outcomes in IPF-related chronic cough using the Leicester Cough Questionnaire (LCQ). Dr. Imran Satia will present poster findings from the Phase 2a RIVER trial, evaluating quality of life in refractory ...
08-26 11:30
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28
Jones Trading analyst Debanjana Chatterjee maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $24 to $28.
08-14 20:52
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30
Cantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $25 to $30.
08-07 20:09
Trevi Therapeutics 2026年第二季度财报：研发支出上升扩大净亏损
Trevi Therapeutics（TRVI）2026年第二季度净亏损1,779.7万美元，每股亏损0.11美元，研发费用升至1,515.2万美元；融资后现金及有价证券达3.189亿美元。
08-07 01:42
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
Trevi Therapeutics, Inc. will host a conference call and webcast on August 6, 2026, at 4:30 p.m. ET, to discuss its financial results and corporate updates for the quarter ended June 30, 2026. The company is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in IPF, non-IPF ILD, and RCC patients. Haduvio has shown significant reduction in cough frequency and improved patient outcomes. No FDA-approved therapies exist for these co...
07-30 20:05
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
Trevi climbs after late-stage trial setback for GSK cough therapy
After GSK (GSK) announced it would discontinue a chronic cough therapy following a late-stage trial failure, Trevi Therapeutics (TRVI), which is advancing a rival candidate, traded higher to reach an ...
07-18 02:04
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Nasdaq Composite falling around 400 points on Friday. Shares of ManpowerGroup Inc (NYSE:MAN) rose sharply after the company reported upbeat second-quarter results and issued third-quarter earnings guidance above expectations. Adjusted earnings were 99 cents per share...
07-17 22:09
